This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Siim, B. G. Articles by Brown, J. M. Search for Related Content PubMed PubMed Citation Articles by Siim, B. G. Articles by Brown, J. M.

Tirapazamine-induced Cytotoxicity and DNA Damage in Transplanted Tumors: Relationship to Tumor Hypoxia¹

Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California 94305-5468 [B. G. S., D. R. M., M. J. D., J. M. B.], and Section of Oncology. Department of Pathology. The University of Auckland, Private Bag 92019, Auckland, New Zealand [B. G. S.]

Tirapazamine (TPZ) is a hypoxia-seiective bioreductive drug currently in Phases II and III clinical trials with both radiotherapy and chemotherapy. The response of tumors to TPZ is expected to depend both on the levels of reductive enzymes that activate the drug to a DNA-damaging and toxic species and on tumor oxygenation. Both of these parameters are likely to vary between individual tumors. In this study, we examined whether the enhancement of radiation damage to tumors by TPZ can be predicted from TPZ-induced DNA damage measured using the comet assay. DNA damage provides a functional end point that is directly related to cell killing and should be dependent on both reductive enzyme activity and hypoxia. We demonstrate that TPZ potentiates tumor cell kill by fractionated radiation in three murine tumors (SCCVII, RIF-1, and EMT6) and two human tumor xenografts (A549 and HT29), with no potentiation observed in a third xenograft (HT1080). Overall, there was no correlation of radiation potentiation and TPZ-induced DNA damage in the tumors, except that the nonresponsive tumor xenograft had significantly lower levels of DNA damage than the other five tumor types. However, there was a large tumor-to-tumor variability in DNA damage within each tumor type. This variability appeared not to result from differences in activity of the reductive enzymes but largely from differences in oxygenation between individual tumors, measured using fluorescent detection of the hypoxia marker EF5. The results, therefore, suggest that the sensitivity of individual tumors to TPZ, although not necessarily the response to TPZ plus radiation, might be assessed from measurements of DNA damage using the comet assay.

¹ This work was supported by Grant CA 15201 from the National Cancer Institute.

² To whom requests for reprints should be addressed.

Received 1/ 8/97. Accepted 5/13/97.

This article has been cited by other articles:

				S. K. Williamson, J. J. Crowley, P. N. Lara Jr, J. McCoy, D. H.M. Lau, R. W. Tucker, G. M. Mills, and D. R. Gandara Phase III Trial of Paclitaxel Plus Carboplatin With or Without Tirapazamine in Advanced Non-Small-Cell Lung Cancer: Southwest Oncology Group Trial S0003 J. Clin. Oncol., December 20, 2005; 23(36): 9097 - 9104. [Abstract] [Full Text] [PDF]

				D. S. Riddick, C. Lee, S. Ramji, E. C. Chinje, R. L. Cowen, K. J. Williams, A. V. Patterson, I. J. Stratford, C. S. Morrow, A. J. Townsend, et al. CANCER CHEMOTHERAPY AND DRUG METABOLISM Drug Metab. Dispos., August 1, 2005; 33(8): 1083 - 1096. [Abstract] [Full Text] [PDF]

				P. P. Breitfeld and W. H. Meyer Rhabdomyosarcoma: New Windows of Opportunity Oncologist, August 1, 2005; 10(7): 518 - 527. [Abstract] [Full Text] [PDF]

				V. M. Aquino, S. D. Weitman, N. J. Winick, S. Blaney, W. L. Furman, J. L. Kepner, P. Bonate, M. Krailo, W. Qu, and M. Bernstein Phase I Trial of Tirapazamine and Cyclophosphamide in Children With Refractory Solid Tumors: A Pediatric Oncology Group Study J. Clin. Oncol., April 15, 2004; 22(8): 1413 - 1419. [Abstract] [Full Text] [PDF]

				R. L. Cowen, K. J. Williams, E. C. Chinje, M. Jaffar, F. C. D. Sheppard, B. A. Telfer, N. S. Wind, and I. J. Stratford Hypoxia Targeted Gene Therapy to Increase the Efficacy of Tirapazamine as an Adjuvant to Radiotherapy: Reversing Tumor Radioresistance and Effecting Cure Cancer Res., February 15, 2004; 64(4): 1396 - 1402. [Abstract] [Full Text] [PDF]

				S. M. Evans, S. Hahn, D. R. Pook, W. T. Jenkins, A. A. Chalian, P. Zhang, C. Stevens, R. Weber, G. Weinstein, I. Benjamin, et al. Detection of Hypoxia in Human Squamous Cell Carcinoma by EF5 Binding Cancer Res., April 1, 2000; 60(7): 2018 - 2024. [Abstract] [Full Text]

				J. Grunstein, W. G. Roberts, O. Mathieu-Costello, D. Hanahan, and R. S. Johnson Tumor-derived Expression of Vascular Endothelial Growth Factor Is a Critical Factor in Tumor Expansion and Vascular Function Cancer Res., April 1, 1999; 59(7): 1592 - 1598. [Abstract] [Full Text] [PDF]